A 38-year-old man from rural Maharashtra presents with a 2-year history of progressive numbness in his feet and hands. On examination, he has well-demarcated hypopigmented macules over his trunk and extensor surfaces with loss of sensation in these lesions. His ulnar and posterior tibial nerves are thickened and tender. Slit-skin smear from the lesion shows acid-fast bacilli. Which of the following best describes the classification of his leprosy based on clinical and bacteriological findings?

Explanation

## Clinical Classification of Leprosy The patient presents with features consistent with **mid-borderline (BB) leprosy** based on the Ridley-Jopling classification. ### Key Clinical Features Presented | Feature | Finding | Significance | |---------|---------|---------------| | Skin lesions | Multiple well-demarcated hypopigmented macules | Intermediate number (5–20 lesions typical) | | Nerve involvement | Bilateral thickened ulnar and posterior tibial nerves | Marked nerve involvement | | Sensory loss | Present in lesions | Indicates cell-mediated immunity | | Slit-skin smear | Acid-fast bacilli positive | Bacterial load present | | Distribution | Trunk and extensor surfaces | Symmetric, intermediate pattern | ### Ridley-Jopling Classification Spectrum **Key Point:** Leprosy classification depends on **clinical morphology, number of lesions, nerve involvement, and bacteriological index (BI)**. ```mermaid flowchart TD A[Leprosy classification]:::outcome --> B{Number of lesions & BI?}:::decision B -->|1 lesion, BI 0-1| C[Tuberculoid TT]:::outcome B -->|Few lesions, BI low| D[Borderline TB BT]:::outcome B -->|5-20 lesions, BI moderate| E[Mid-borderline BB]:::outcome B -->|Many lesions, BI high| F[Borderline LL BL]:::outcome B -->|Innumerable lesions, BI very high| G[Lepromatous LL]:::outcome E --> H[Unstable form - prone to reactions]:::action ``` ### Why Mid-Borderline (BB)? **High-Yield:** Mid-borderline leprosy is the **most unstable form** of the disease and is **most prone to both Type 1 (reversal) and Type 2 (erythema nodosum leprosum) reactions**. 1. **Multiple lesions (>5)** but not innumerable → rules out TT and LL 2. **Positive slit-skin smear** → rules out pure TT (which is paucibacillary) 3. **Marked nerve thickening and involvement** → characteristic of BB 4. **Well-demarcated lesions with sensory loss** → indicates intermediate cell-mediated immunity 5. **Symmetric distribution** → typical of BB ### Bacteriological Index (BI) in BB Leprosy **Clinical Pearl:** In mid-borderline leprosy, the BI is typically **3–4+** (moderate bacterial load), intermediate between tuberculoid (BI 0–1) and lepromatous (BI 5–6). ### Management Implications **Key Point:** BB leprosy requires **12-month multidrug therapy (MDT)** with: - Rifampicin 600 mg monthly - Dapsone 100 mg daily - Clofazimine 50 mg daily + 300 mg monthly **Warning:** Patients with BB leprosy must be monitored closely for **Type 1 lepra reactions** (reversal reactions), which can occur during or after treatment and cause acute nerve damage.